Losartan shows limited benefit in preclinical models of Geleophysic dysplasia
Alejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin · 2026
Read Losartan shows limited benefit in preclinical models of Geleophysic dysplasia by Alejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13574788.txt.
Description
Alejo A Morales, with six colleagues, reports a 2026 test of a common blood-pressure drug in lab models of a rare bone disorder. Geleophysic dysplasia stunts growth, stiffens joints, and strains the heart and lungs, often killing young. Faults in three genes tangle the tissue mesh and may overdrive a growth signal the drug is known to calm.
Losartan blocks a hormone receptor and has eased similar signal-driven disease in other settings. The team gave it in preclinical models of this dysplasia to judge benefit before any human use. Rare-disease drugs often jump from such models straight to small trials, so a clear lab verdict matters. The title states the outcome plainly: benefit was limited in these models. The work steers the field away from a tempting shortcut and toward targets with firmer ground.
Catalog record
| CREATOR | Alejo A Morales, Vladimir Camarena, LéShon Peart, Sarah Smithson, Katherina Walz, Gaofeng Wang, Mustafa Tekin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50804 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |